ZVSA - ZyVersa Therapeutics, Inc. Total Debt to Capital

The available price action vector for the total debt-to-equity ratio is 0.00. ZyVersa Therapeutics relies on outsourced molecule synthesis to minimize capital expenditures, while its US-based R&D operations are shielded from geopolitical risks. ZyVersa Therapeutics develops innovative treatments for renal pathologies, utilizing an inflammasome platform for the therapy of rare inflammatory conditions.

This ratio determines the business's dependence on borrowed funds by comparing total liabilities to equity to assess financial stability. By analyzing the current total debt leverage, an investor can see the efficiency of the ZyVersa Therapeutics (ZVSA) fabless model, where the absence of proprietary plants and the use of CMO contractors minimize capital expenditures and keep the debt load at a safe level.